Zhitong Finance App News, Tongyuankang Pharmaceutical-B (02410) announced that the new-generation EGFR-TKI innovative drug deuterium methanesulfonate tablets (TY-9591 tablets) independently developed by the company has been approved by the China National Drug Administration (NMPA) for conditional marketing. The indications are that they have epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutations, accompanied by advanced non-local metastases of central nervous system (CNS) metastases Cellular lung cancer (NSCLC) adults First-line treatment for patients.

Aitinib mesylate tablets are a new generation of highly selective, irreversible oral EGFR-TKI independently developed by our company. It is an innovative variant of deuterium-generation differentiation for osimitinib. Through unique structural optimization, the drug effectively reduces the production of toxic metabolites, has better pharmacokinetic characteristics, and has shown outstanding clinical efficacy and safety advantages in EGFR 19del and L858r sensitive lung cancer patients. At present, the company has deployed multiple clinical studies of single drugs and combination drugs around this product, covering all types of segmented indications for advanced non-small cell lung cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.